Staging preview: health content pending qualified review

AOD-9604 2 mg

Also searched as: aod 9604, aod9604

Sold as AOD9604 2mg

$25 In stock

Strength
Ships from

For research use only. Not for human or veterinary use.

Ships from the USA or Canada. Shipping details

AOD-9604 is a synthetic peptide of 16 amino acids: residues 177 to 191 of human growth hormone with an added tyrosine at the front.1 Developed in Australia as a possible obesity drug, it failed its largest trial: weight loss was not significantly greater than with placebo.7 It is not an FDA-approved drug.1 This vial holds 2 mg of white freeze-dried solid for laboratory research.5

Specifications

Sequence (one-letter code)YLRIVQCRSVEGSCGF, with a disulfide bond between Cys7 and Cys144
Sequence (three-letter code)H-Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH4
Length16 amino acids: hGH residues 177 to 191 plus an N-terminal tyrosine1
Molecular formulaC78H123N23O23S2 (free base); C80H127N23O25S2 (acetate salt)21
Molar mass1815.1 g/mol (free base); 1,875.1 g/mol (acetate salt)21
CAS number221231-10-3 (free base); some suppliers report 386264-39-7 instead31
PubChem CID713006302
FormWhite lyophilized (freeze-dried) solid, as listed by the supplier5
Vial contents2 mg of AOD-9604 per vial; no diluent included5
Strength2 mg
Ships fromUSA, Canada
CategoriesGrowth Hormone Peptides, Muscle Growth Peptides
StorageThe supplier lists a shelf life of 36 months at -20 °C and 30 days at 2 to 8 °C, without saying whether the 30 days applies before or after mixing.5 These are supplier figures, not an official standard: AOD-9604 has no USP or National Formulary monograph.1

Bulk and wholesale orders

Labs that need AOD-9604 in larger quantities can apply for a wholesale account. Bulk terms are confirmed on application.

Questions about AOD-9604

About AOD-9604

AOD-9604 copies residues 177 to 191 from the tail of human growth hormone (hGH), with one tyrosine added at the front.1 Its two cysteines, at positions 7 and 14, are joined by a disulfide bond.4 The Melbourne company Metabolic Pharmaceuticals developed and patented the peptide in the late 1990s as a candidate obesity drug.17

In obese rats and mice it reduced weight gain.89 In people, the developer's largest trial (536 adults) found weight loss versus placebo too small to reach statistical significance, and the company ended obesity development in February 2007.7 FDA concluded in 2024 that evidence of effectiveness for obesity is lacking for any route.1

This page lists AOD-9604 for sale as a 2 mg research vial, with the AOD-9604 price in the selector above. Read What is AOD-9604? for side effects and study doses before you buy AOD-9604 online for a study.

Research highlights

  • Obese rats (2000): 19 days of AOD-9604 by mouth cut weight gain by more than half (15.8 g against 35.6 g), with no loss of insulin sensitivity.8
  • Obese mice and cell tests (2001): 14 days of AOD-9604 or hGH reduced weight gain and raised fat oxidation; unlike hGH, AOD-9604 did not raise blood sugar, bind the hGH receptor or make receptor-bearing cells multiply.9
  • Rabbit knees (2015): in 32 rabbits with induced osteoarthritis, weekly joint injections improved cartilage repair, more so when combined with hyaluronic acid.10
  • 12-week trial (300 obese adults, capsules by mouth): all five dose groups lost more weight on average than placebo, but the best group fell short of significance overall (p=0.1), reaching it only in the female subgroup.67
  • 24-week OPTIONS trial (536 obese adults enrolled, tablets by mouth, with diet and exercise): weight loss beyond placebo was under 1 kg in every dose group at 12 and 24 weeks, too small to be statistically significant.7
  • Human safety (six developer-funded trials, 893 adults, by mouth or by vein): the sponsor's authors reported side effects similar to placebo, no change in IGF-1, no worsening of glucose tolerance and no antibodies in those tested.6 FDA's 2024 review raised concerns about cancers reported in the 12-week trial and found too little information to support long-term safety.1

Regulatory status

AOD-9604 is not an ingredient of any FDA-approved drug, and it has no USP or National Formulary monograph.1 In a 12 to 0 vote on December 4, 2024, FDA's Pharmacy Compounding Advisory Committee advised against placing it on the 503A Bulks List, FDA's list of bulk drug substances that can be used to compound drugs under section 503A.111 The 2026 WADA Prohibited List names it under S2.2.3 as a growth hormone fragment, prohibited in and out of competition.12 The vial is labeled: For research use only. Not for human or veterinary use.

Handling and storage

According to a supplier certificate cited by FDA, up to 2 mg of the free base dissolves in 1 mL of water, so each 1 mg needs at least 0.5 mL.1 FDA also notes that peptides like AOD-9604 can clump and degrade with changes in pH, temperature, concentration or impurities.1 Lab steps and concentration math are in How to reconstitute AOD-9604, general technique in How to reconstitute a peptide vial, and the reconstitution calculator does the division. Diluent is not included when you buy AOD-9604, so bacteriostatic water is listed separately.5

Frequently asked questions

What strengths of AOD-9604 are available, and where do they ship from?

This page lists AOD-9604 at 2 mg per vial, from $25. Orders ship from the USA and Canada to addresses across the United States, and the selector shows stock for each shipping origin before the vial goes in the cart. Delivery options are on the shipping page, and return terms are on the returns page.

How should AOD-9604 be stored when it arrives?

Keep the sealed vial closed, dry and cold. A safety data sheet cited by FDA says to keep the free base dry in closed containers: 3 years at -18 °C, 1 year at 0 to 7 °C, half a year at 7 to 30 °C.1 Figures differ between suppliers: a product insert cited by FDA gives the acetate form more than four years at -20 °C.1 Storage after mixing is covered in How to reconstitute AOD-9604.

Is there a certificate of analysis for AOD-9604?

See the lab results page for certificate information, or ask about a specific lot through the contact page. Check which tests any certificate covers: in its 2024 review, FDA found that specific tests for impurities, aggregates, microbes and bacterial endotoxin were missing from the certificate submitted to it and from public sources.1 A reported molecular mass can be compared with 1815.1 g/mol for the free base2 or 1,875.1 g/mol for the acetate salt.1

What supplies are used with an AOD-9604 vial?

The supplies listed with this vial are bacteriostatic water, a 3 mL Luer-Lok syringe, an 18G 1-inch needle, insulin syringes and alcohol swabs. In the two early IV trials, the study drug was supplied freeze-dried and dissolved in sterile water for injection before use.6

Is AOD-9604 for human use?

No. This vial is sold for laboratory research and labeled: For research use only. Not for human or veterinary use. AOD-9604 is not an ingredient of any FDA-approved drug, and FDA identified no human data for injection under the skin.1 Human trials gave it only by mouth or by vein.6 WADA bans it in sport at all times.12

Written by D2C Peptides Editorial Team.

Pending qualified review.

Updated .

Sources

  1. FDA Briefing Document, Pharmacy Compounding Advisory Committee, December 4, 2024: AOD-9604-Related Bulk Drug Substances (introduction). U.S. Food and Drug Administration, 2024.
  2. Aod-9604, PubChem compound CID 71300630 (computed properties). PubChem, National Library of Medicine (NIH), 2026.
  3. Aod-9604 (CID 71300630): CAS section. PubChem, National Library of Medicine (NIH), 2026.
  4. Aod-9604 (CID 71300630): biologic description and sequence. PubChem, National Library of Medicine (NIH), 2026.
  5. Supplier product specification.
  6. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans (Stier H, Vos E, Kenley D): results overview. Journal of Endocrinology and Metabolism 3(1-2):7-15, 2013.
  7. Metabolic's obesity drug: Phase 2B clinical trial results (ASX announcement, 21 February 2007, in an SEC filing, file no. 82-34880). Metabolic Pharmaceuticals Limited, 2007.
  8. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone (Ng FM et al.), PubMed abstract: dosing. Hormone Research 53(6):274-8, 2000.
  9. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment (Heffernan MA et al.), PubMed abstract. International Journal of Obesity 25(10):1442-9, 2001.
  10. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model (Kwon DR, Park GY), PubMed abstract: methods. Annals of Clinical and Laboratory Science 45(4):426-32, 2015.
  11. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024. U.S. Food and Drug Administration, 2024.
  12. Tractatenblad 2026, 25: The 2026 Prohibited List, World Anti-Doping Code (S2.2.3). Netherlands Ministry of Foreign Affairs, official treaty series reproducing the WADA list, 2026.